J&J/Neutrogena
This article was originally published in The Rose Sheet
Executive Summary
Waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to Johnson & Johnson's proposed acquisition of Neutrogena has expired, J&J's announces. The firm's tender offer for all outstanding shares of Neutrogena was scheduled to expire Sept. 23